Bupropion/naltrexone

Papers on bupropion/naltrexone

8 papers

Tuesday, June 9

Diabetes, Obesity & MetabolismJun 9

Risk of Age-Related Ocular Diseases in Non-Diabetic Adults With Obesity Using Glucagon-Like Peptide 1 Receptor Agonists

Cohort study of 68,536 peopleObesity

Friday, March 20

Obesity PillarsMar 20

Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach

ReviewIndustry & policy

Thursday, March 5

ObesityMar 5

Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach

ReviewIndustry & policy

Saturday, December 27

Ophthalmology RetinaDec 27

Rate of Age-Related Macular Degeneration in Patients Prescribed Glucagon-Like Peptide-1 Receptor Agonists or Other Weight Loss Therapies

Cohort study of 60,336 peopleAge-related macular degeneration

Monday, November 3

AHA Scientific Sessions 2025 AbstractNov 3

Real-World Effectiveness of GLP-1 Receptor Agonists on Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF).

Cohort study of 107,252 peopleGLP-1 receptor agonists

Tuesday, October 7

World Journal of GastroenterologyOct 7

Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review

ReviewMetabolic dysfunction-associated steatotic liver disease

Tuesday, April 22

DiseasesApr 22

Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review

ReviewInterventions

Monday, November 25

Archives of Endocrinology and MetabolismNov 25

Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM)